Company Of The Day: Pfizer

+1.83%
Upside
28.88
Market
29.41
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

Pfizer (NYSE:PFE) posted a stronger-than-expected set of Q3 2022 results. Although revenue declined by about 6% versus last year to $22.6 billion, it came in ahead of estimates. Adjusted earnings stood at $1.78 per share, up 40% versus last year.

Why?

Relevant Articles
  1. Is Pfizer Stock Fully Valued At $28?
  2. What Factors Will Drive Pfizer’s Q1 Performance?
  3. After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
  4. Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
  5. Should You Pick Pfizer Stock At $30?
  6. Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?

While sales were weighed down by lower Covid-19 vaccine sales, this was partly offset by strong sales of Pfizer’s antiviral drug Paxlovid as well as Prevnar and Eliquis.

So What?

PFE stock was up by about 3% in Tuesday’s trading.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

Returns Nov 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 PFE Return 3% -19% 48%
 S&P 500 Return 0% -19% 72%
 Trefis Multi-Strategy Portfolio 0% -22% 208%

[1] Month-to-date and year-to-date as of 11/2/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates